• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

NPJ Biofilms Microbiomes . Gut microbiota dysbiosis is associated with altered tryptophan metabolism and dysregulated inflammatory response in COVID

tetano

Editor, Senior Moderator
NPJ Biofilms Microbiomes


. 2024 Aug 1;10(1):66.
doi: 10.1038/s41522-024-00538-0. Gut microbiota dysbiosis is associated with altered tryptophan metabolism and dysregulated inflammatory response in COVID-19

Morgan Essex[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Belén Millet Pascual-Leone[SUP] #[/SUP][SUP] 4 [/SUP], Ulrike Löber[SUP] 1 2 3 [/SUP], Mathias Kuhring[SUP] 2 5 6 [/SUP], Bowen Zhang[SUP] 7 8 9 [/SUP], Ulrike Brüning[SUP] 5 [/SUP], Raphaela Fritsche-Guenther[SUP] 5 [/SUP], Marta Krzanowski[SUP] 4 [/SUP], Facundo Fiocca Vernengo[SUP] 4 [/SUP], Sophia Brumhard[SUP] 4 [/SUP], Ivo Röwekamp[SUP] 4 [/SUP], Agata Anna Bielecka[SUP] 10 11 [/SUP], Till Robin Lesker[SUP] 10 [/SUP], Emanuel Wyler[SUP] 12 [/SUP], Markus Landthaler[SUP] 12 13 [/SUP], Andrej Mantei[SUP] 14 [/SUP], Christian Meisel[SUP] 14 15 [/SUP], Sandra Caesar[SUP] 4 [/SUP], Charlotte Thibeault[SUP] 4 [/SUP], Victor M Corman[SUP] 14 16 17 [/SUP], Lajos Marko[SUP] 1 2 3 18 [/SUP], Norbert Suttorp[SUP] 4 19 [/SUP], Till Strowig[SUP] 7 10 11 [/SUP], Florian Kurth[SUP] 4 [/SUP], Leif E Sander[SUP] 4 19 [/SUP], Yang Li[SUP] 7 8 [/SUP], Jennifer A Kirwan[SUP] 2 5 20 [/SUP], Sofia K Forslund[SUP] 1 2 3 18 21 [/SUP], Bastian Opitz[SUP] 22 23 24 [/SUP]



Affiliations
Abstract

The clinical course of COVID-19 is variable and often unpredictable. To test the hypothesis that disease progression and inflammatory responses associate with alterations in the microbiome and metabolome, we analyzed metagenome, metabolome, cytokine, and transcriptome profiles of repeated samples from hospitalized COVID-19 patients and uninfected controls, and leveraged clinical information and post-hoc confounder analysis. Severe COVID-19 was associated with a depletion of beneficial intestinal microbes, whereas oropharyngeal microbiota disturbance was mainly linked to antibiotic use. COVID-19 severity was also associated with enhanced plasma concentrations of kynurenine and reduced levels of several other tryptophan metabolites, lysophosphatidylcholines, and secondary bile acids. Moreover, reduced concentrations of various tryptophan metabolites were associated with depletion of Faecalibacterium, and tryptophan decrease and kynurenine increase were linked to enhanced production of inflammatory cytokines. Collectively, our study identifies correlated microbiome and metabolome alterations as a potential contributor to inflammatory dysregulation in severe COVID-19.


 
Back
Top Bottom